Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis

Journal of Experimental Medicine

Volumn 194, Issue 12, 2001, Pages 1801-1811

  Singh, Avneesh K ^a   Wilson, Michael T ^a   Hong, Seokmann ^a   Olivares Villagómez, Danyvid ^a   Du, Caigan ^a   Stanic, Aleksandar K ^a   Joyce, Sebastian ^a   Sriram, Subramaniam ^a   Koezuka, Yasuhiko ^b   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KIRIN BREWERY CO LTD   (Japan)

Author keywords

Autoimmunity; CD1d; Experimental autoimmune encephalomyelitis; Immunotherapy; NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BETA GALACTOSYLCERAMIDE; CD1 ANTIGEN; CD1D ANTIGEN; GALACTOSYLCERAMIDE; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOPATHOGENESIS; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; KNOCKOUT MOUSE; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD1; AUTOIMMUNITY; CYTOTOXICITY, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GALACTOSYLCERAMIDES; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS;

EID: 0035905471     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.12.1801     Document Type: Article

References (74)

1. Assessment of animal models for MS and demyelinating disease in the design of rational therapy
2. Lymphotoxin and tumor necrosis factor-α production by myelin basic protein-specific T cell clones correlates with encephalitogenicity
3. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis
4. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta
5. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo
6. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain
7. Redirecting Th1 and Th2 responses in autoimmune disease
8. Genetic models for CNS inflammation
9. Mouse CD1-specific NK1 T cells: Development, specificity, and function
10. Lipid antigen presentation in the immune system: Lessons learned from CD1d knockout mice
11. NKT cells: Facts, functions and fallacies
12. CD1d and natural T cells: How their properties jump-start the immune system
13. - T cells
14. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4
15. + T cell development and early IL-4 production in CD1-deficient mice
16. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells
17. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi
18. + Vα14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major
19. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus
20. Differential tumor surveillance by natural killer (NK) and NKT cells
21. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
22. Immune suppression and skin cancer development: Regulation by NKT cells
23. +-like thymocytes in the NOD mouse
24. - T-cell deficiency and IDDM in NOD/Lt mice
25. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus
26. + T cells that promptly produce interleukin 4
27. + NK T cells associated with disease development in autoimmune-prone mice
28. CD1d-restricted NKT cells: An interstrain comparison
29. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis
30. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes
31. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy
32. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage
33. + double-negative regulatory natural killer T cells in autoimmune diseases
34. - Vα24JαQ T cells in peripheral blood of patients with relapsing-remitting multiple sclerosis
35. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site
36. Immune privilege: Keeping an eye on natural killer T cells
37. + Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice
38. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance
39. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
40. Murine CD1d-restricted T cell recognition of cellular lipids
41. Agelasphins, novel α-galactosylceramides from the marine sponge Agelas Mauritianus
42. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
43. + NK T lymphocytes
44. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells
45. Activation of human Vα24 NKT cells by α-glycosylceramide in a CD1d-restricted and Vα24 TCR-mediated manner
46. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
47. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
48. Cutting edge: Activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
49. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
50. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells
51. α-Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells
52. + T cells upon NK T or T cell activation
53. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline
54. Structure-activity relationship of α-galactosylceramides against B16-bearing mice
55. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
56. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
57. + T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis
58. + T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice
59. + T cells in murine experimental allergic encephalomyelitis
60. -/- mice
61. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering
62. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice
63. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells
64. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice
65. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes
66. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes
67. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice
68. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide
69. KRN7000, an NKT cell enhancer, in patients with solid tumors - A phase I study of the EORTC BTDG
70. + T cells
71. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: A pro-Th2 effect of IL-18 exerted through NKT cells
72. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells
73. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways
74. H2 bias of natural killer T cells